# Kestra Medical

> Kestra Medical develops prescription wearable cardiac devices and connected recovery tools. Its ASSURE wearable cardioverter defibrillator monitors rhythms and automatically treats certain life-threatening ventricular arrhythmias, supported by a patient app, CareStation and patient services. It earns revenue through monthly device leases reimbursed by insurers and patients.

- **Founded:** 2014
- **Headquarters:** Kirkland, United States
- **Founders:** Brian Webster (Co-founder, President and CEO), Traci Umberger (Co-founder, Chief Administrative Officer and General Counsel)
- **Products:** ASSURE Wearable Cardioverter Defibrillator, Cardiac Recovery System, Kestra CareStation, ASSURE Patient App, ASSURE Assist
- **Notable:** FDA approval of ASSURE WCD on July 27, 2021., Full commercial launch in August 2022., Nasdaq listing under KMTS in March 2025.

## Products & services

- **ASSURE Wearable Cardioverter Defibrillator** — Prescription external wearable system that monitors ECG and automatically delivers defibrillation for dangerous ventricular arrhythmias; FDA approved July 2021, fully commercially launched August 2022.
- **Cardiac Recovery System** — Integrated platform combining the ASSURE WCD, patient app, remote data platform and support services.
- **Kestra CareStation** — Cloud-based clinician platform for rhythm reports, wear time, activity trends and configurable notifications.
- **ASSURE Patient App** — Patient tool for data transmission, wear time, activity, education and troubleshooting.
- **ASSURE Assist** — Post-shock assistance service with phone, connectivity, proximity and permission requirements.
- **ASSURE Wearable ECG** — Nontherapeutic wearable ECG for continued monitoring after ASSURE WCD use; does not deliver shocks.

## Achievements

- FDA approval of ASSURE WCD on July 27, 2021.
- Full commercial launch in August 2022.
- Nasdaq listing under KMTS in March 2025.
- ACE-PAS enrolled 21,612 patients; primary results announced November 2025 reported median use exceeding 23 hours/day and 94% with no false positive shock alarms.
- Nearly 40,000 patients served by April 30, 2026.
- Fiscal 2026 revenue grew 59% to US$95.1 million.

## Latest updates

- **2026-10** — October 1: company announced a five-star rating on Newsweek’s 2026 America’s Greatest Mid-Market Companies list.
- **2026-09** — September 14: reported US$31.0 million quarterly revenue, US$44.1 million net loss, and raised fiscal 2027 revenue guidance to US$141 million.
- **2026-09** — September 10: named Daniel Finney Vice President of Research & Development.
- **2026-08** — August 26: appointed Curtis Kopf Senior Vice President of Customer Experience.
- **2026-07** — Announced up to US$200 million loan facility; US$75 million funded at closing.
- **2026-04** — Released Enhanced ASSURE Detection Algorithm, informed by post-approval registry data.
- **2026-01** — Announced strategic collaboration with Biobeat.

## Links

- Website: https://www.kestramedical.com/
- LinkedIn: https://www.linkedin.com/company/kestra-medical-technologies-inc./
- Twitter/X: https://twitter.com/kestramedical
- Facebook: https://www.facebook.com/KestraMedical/

---

Profile page: https://yespress.io/kestra-medical
Published by YesPress — https://yespress.io
Last updated: 2026-10-25